Canada’s particle physics laboratory TRIUMF is making a push to be a future world leader in the production of a special radioactive isotope nicknamed the “rarest drug on Earth,” which can deliver devastating amounts of energy to single cancer cells, without harming nearby tissue. Read the article here.
When Can Patients With Gleason 6 Prostate Cancer Safely Undergo Active Surveillance? A roundtable discussion. Read the article here.
When Can Patients With Gleason 6 Prostate Cancer Safely Undergo Active Surveillance? Read More »
Larry Goldenberg, MD demonstrated his support for using active surveillance in intermediate-risk prostate cancer. Read the article here.
Active Surveillance for Intermediate Risk Prostate Cancer Read More »
An overview on statin use in prostate cancer. Read the article here.
Statin Use in Prostate Cancer Read More »
A recent article exploring how physicians who manage prostate cancer regularly think about active surveillance and how to discuss this with their patients. Read the article here.
How 48 doctors think about active surveillance Read More »
Jan Manarite, executive vice president of Prostate Cancer International, discusses what a man with prostate cancer should do when his disease is progressing and his PSA levels are rising while on hormone therapy. Watch the video here.
When Facing Metastatic Prostate Cancer, Know What to Ask Your Doctor Read More »
A presentation of work assessing the feasibility of implementing a diet-based intervention in men with prostate cancer. Watch the interview here.
Diet Intervention in Men on Active Surveillance for Prostate Cancer Read More »
This is a comprehensive article from Esquire about most aspects of prostate cancer. Read the article.
An Optimist’s Guide to Your Prostate Read More »
A discussion of radiation techniques and genomic testing in prostate cancer. Read the article here.
Expert Discusses Radiation Techniques, Genomic Testing in Prostate Cancer Read More »
The landmark Prostate Cancer Prevention Trial has delivered a final verdict. Finasteride, a common hormone-blocking drug, reduces mens’ risk of getting prostate cancer without increasing their risk of dying from the disease. Initial study findings suggested there may be a link between use of the drug and a more lethal form of prostate cancer, but long-term follow-up shows that is not true. Read the article here.
Finasteride does not increase risk of prostate cancer death Read More »